Diabetic Ketoacidosis

vTv Drug Candidate Lowers Blood Sugar Without Increasing DKA Risk

Blood Sugar, Clinical Data, Clinical Trials, Diabetic Ketoacidosis, Insulin Pumps, R&D, SGLT2 Inhibitors, Type 1 Diabetes

High Point, North Carolina-based vTv Therapeutics announced positive results from a mechanistic study of TTP399 in type 1 diabetes patients.

October 12, 2021/by Andrew Humphreys

FDA Panel Gives Approval Nod to Diabetes Drug

Business, Diabetic Ketoacidosis, Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), Human Anti-CD38 Monoclonal Antibody, PDUFA, Shares, Type 1 Diabetes

Shares of Provention Bio Inc. plunged in trading after a Food and Drug Administration advisory committee narrowly supported the company’s diabetes prevention drug, teplizumab.

May 28, 2021/by Andrew Humphreys

FDA denies Lexicon appeal against drug rejection

Approval Rejection, Center for Drug Evaluation and Research (CDER), Diabetic Ketoacidosis, FDA, FDA/Regulatory, Partnership, Shares, Type 1 Diabetes

The U.S. FDA denied Lexicon Pharmaceuticals Inc.’s appeal against the rejection of the add-on treatment Zynquista for type 1 diabetes, marking the company’s third major setback during 2019.

December 2, 2019/by Reuters Health

Sanofi to pay Lexicon for terminated partnership

Acids, Business, Clinical Studies, Diabetes, Diabetic Ketoacidosis, Insulin, Ketones, Partnerships, Shares, Terminations, Type 1 Diabetes

Lexicon Pharmaceuticals Inc. said France’s Sanofi SA will pay the Texas-based drugmaker $260 million for the termination of their partnership to develop the diabetes drug Zynquista.

September 10, 2019/by Reuters Health

THOUSAND OAKS, Calif. and KENILWORTH, N.J., Dec. 4, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a cancer […]

December 4, 2015/by PR Newswire